ArticleScientific reports2025
Pressurized intraperitoneal aerosol chemotherapy enhances cisplatin efficacy in colorectal cancer organoids.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PIPAC's Path: When Details Drive Progress.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is an emerging method that delivers chemotherapeutic agents as aerosols directly into the peritoneal cavity to overcome poor tissue penetration. Although early clinical outcomes are promising, challenges remain, such as variable patient responses and the lack of appropriate preclinical models. In this study, we investigated the efficacy of PIPAC combined with three cytotoxic agents (Cisplatin, Oxaliplatin, and Paclitaxel) using patient-derived colorectal cancer organoid models. Our results demonstrates that PIPAC, especially when combined with Cisplatin, significantly enhances the cytotoxicity against colorectal cancer organoids and modulates key cancer-related pathways. Transcriptomic analysis revealed significant alterations in gene expression patterns under PIPAC conditions, with notable impacts on cancer-related pathways such as epithelial-mesenchymal-transition and KRAS signaling. Pathway analysis further elucidated the modulation of cell-cycle related and oncogenic pathways by PIPAC, providing insights into its mechanism of action. These key findings suggest that PIPAC, particularly with Cisplatin, can enhance chemotherapeutic efficacy via transcriptomic modulation, supporting its potential clinical application in treating peritoneal carcinomatosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.